UK-based Proximagen Neuroscience, a spin-out from King's College London, says that, in full-year 2005, its turnover increased 51% to L878,000 ($1.5 million) compared with 2004 on the stregth of six new contracts it signed during the year.
The London-based firm noted that gross margin was 54%, compared with 45% for the year to November 2004, "reflecting increased efficiency in laboratory operations where the escalation in activity on our internal programs enabled it to use resources more effectively."
The firm stated that its net assets at the end of the year totaled L13.2 million, an increase of L12.8 million due primarily to the net proceeds of its Inital Public Offering in March 2005, which raised L14.5 million (Marketletter April 4, 2005).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze